4//SEC Filing
Loven Jakob 4
Accession 0001209191-21-026871
CIK 0001741830other
Filed
Apr 14, 8:00 PM ET
Accepted
Apr 15, 6:57 PM ET
Size
17.2 KB
Accession
0001209191-21-026871
Insider Transaction Report
Form 4
Kronos Bio, Inc.KRON
Loven Jakob
Director
Transactions
- Sale
Common Stock
2021-04-13$24.40/sh−5,738$140,007→ 1,428,993 total(indirect: See footnote) - Sale
Common Stock
2021-04-14$22.38/sh−13,698$306,561→ 1,414,010 total(indirect: See footnote) - Sale
Common Stock
2021-04-13$25.18/sh−1,285$32,356→ 1,427,708 total(indirect: See footnote) - Sale
Common Stock
2021-04-14$23.10/sh−18,938$437,468→ 1,395,072 total(indirect: See footnote) - Sale
Common Stock
2021-04-15$21.78/sh−24,818$540,536→ 1,370,254 total(indirect: See footnote) - Sale
Common Stock
2021-04-13$23.35/sh−9,997$233,430→ 1,434,731 total(indirect: See footnote)
Footnotes (8)
- [F1]Shares were sold pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.74 to $23.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The securities are held by Nextech V Oncology S.C.S, SICA-SIF ("Nextech V"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG ("Nextech AG"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.80 to $24.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 to $25.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.88 to $23.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $22.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Kronos Bio, Inc.
CIK 0001741830
Entity typeother
Related Parties
1- filerCIK 0001753644
Filing Metadata
- Form type
- 4
- Filed
- Apr 14, 8:00 PM ET
- Accepted
- Apr 15, 6:57 PM ET
- Size
- 17.2 KB